Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2006-03-21
2006-03-21
Wang, Shengjun (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S173000, C514S172000, C514S174000, C514S175000
Reexamination Certificate
active
07015210
ABSTRACT:
A method for treating or preventing ophthalmic disorders comprising the administration of one or more aldosterone receptor antagonists that contain a 9,11-epoxy moiety, such as eplerenone is disclosed. The method results in a reduction of intraocular pressure which treats or prevents the ophthalmic disorders. Among the disorders are intraocular hypertension, glaucoma, low tension glaucoma, age-related macular degeneration (AMD), macular edema, and diabetic retinopathy.As glucocorticoids and mineralocorticoids also cause the retention of ions, such as sodium and potassium, where aldosterone receptors are located, aldosterone receptor antagonists that contain a 9,11-epoxy moiety, such as eplerenone, also can be administered to modulate the intraocular concentration of ions. Thus, aldosterone receptor antagonists can be administered to maintain an intraocular ionic environment that is beneficial to intraocular cell survival.
REFERENCES:
patent: 3711602 (1973-01-01), Herschler
patent: 4177267 (1979-12-01), Herschler
patent: 4552871 (1985-11-01), Grob et al.
patent: 4559332 (1985-12-01), Grob et al.
patent: 4670551 (1987-06-01), Biollaz
patent: 5132400 (1992-07-01), Gammill et al.
patent: 5270322 (1993-12-01), Ries et al.
patent: 5385925 (1995-01-01), Narr et al.
patent: 6011023 (2000-01-01), Clark et al.
patent: 6172054 (2001-01-01), Clark
patent: 0 628 313 (1994-12-01), None
patent: 95/15166 (1995-06-01), None
patent: 96/40255 (1996-12-01), None
patent: 01/87284 (2001-11-01), None
patent: 01/95893 (2001-12-01), None
patent: 02/09760 (2002-02-01), None
Antihypertensive Treatment of Heart Failure Aldosterone Antagonist, Drugs of the Future, 1999, 24(5), pp. 488-501.
Ashbrook Charles
Pharmacia Corporation
Thomas Robert S.
Wang Shengjun
LandOfFree
Methods of treating ophthalmic disorders with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating ophthalmic disorders with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating ophthalmic disorders with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3593574